Indeed, the inhibition of DNA-PK is a very promising target in anticancer research since the efficacy of radiotherapy and some chemotherapies, working by inducing DNA DSBs in tumor cells, can be compromised by the efficient repair of DNA damage through activation DNA-PK [65]. This evidence concerns the gene PRKDC and neoplasm.